Posts

Posted on

Union Bank of the Philippines Embraces NCR ATM as a Service to Enhance Self-Service Banking

Union Bank of the Philippines Embraces NCR ATM as a Service to Enhance Self-Service Banking

ATLANTA–(BUSINESS WIRE)–NCR Corporation (NYSE: NCR), a leading enterprise technology provider, announced today that Union Bank of the Philippines has selected NCR’s ATM as a Service solution to revolutionize, connect and streamline their self-service banking operations.

UnionBank is committed to being the Philippines’ foremost digital-first bank, catering to the evolving needs of Filipinos nationwide. By leveraging NCR ATM as a Service, UnionBank’s customers will enjoy enhanced availability, improved uptime and expanded capabilities at their ATMs. By transferring the maintenance and management of their ATM fleet, comprising over 400 ATMs, to NCR, the bank aims to enhance operational efficiencies while bolstering compliance and security measures.

“We have a proven history of embracing innovation, and NCR’s ATM as a Service solution aligns perfectly with our mission to modernize our self-service channel and accelerate the delivery of new features and functionality to the market,” said Dennis Omila, Executive Vice President, Chief Technology and Operations Officer at UnionBank. Magz Magbanua, Senior Vice President, Head of Corporate and Digital Operations, added, “NCR’s technology, operational expertise, and strategic guidance will support our bank as we expand our ATM network, not only in terms of physical presence but also in capabilities, enabling us to unlock new value for our customers.”

“UnionBank knows the critical role evolving their technology strategy plays in meeting customers’ changing expectations,” said Stuart Mackinnon, EVP, ATM Group, NCR Banking. “In choosing our ATM as a Service solution, they entrust hardware and software management to an experienced provider, freeing time and resources to focus on growth and strengthening customer relationships. We are proud to support UnionBank and help power the expansion and evolution of their self-service banking network.”

About UnionBank

Union Bank of the Philippines (UnionBank) embraces the future of banking and is committed to be the Philippines’ leading digital bank to best serve the growing needs of Filipinos everywhere. It has consistently been recognized as of one of Asia’s leading companies, ranking among the country’s top universal banks in terms of profitability and efficiency. With its drive to “Tech Up Pilipinas” and be an enabler of the Philippines’ push to be a G20 country by 2050, UnionBank stands firm in its promise to power the future of banking by co-creating innovations for its customers and for a better world!

About NCR Corporation

NCR Corporation (NYSE: NCR) is a leader in transforming, connecting, and running technology platforms for self-directed banking, stores, and restaurants. NCR is headquartered in Atlanta, Georgia, with 35,000 employees globally. NCR is a trademark of NCR Corporation in the United States and other countries.

Web site: www.ncr.com

Twitter: @NCRCorporation

Facebook: www.facebook.com/ncrcorp

LinkedIn: www.linkedin.com/company/ncr-corporation

YouTube: www.youtube.com/user/ncrcorporation

Scott Sykes

NCR Corporation

[email protected]

KEYWORDS: United States North America Philippines Asia Pacific Georgia

INDUSTRY KEYWORDS: Banking Online Retail Technology Professional Services Payments Electronic Commerce Other Technology Retail Software Fintech Finance

MEDIA:

Logo
Logo
Posted on

Redfin Reports Home Prices Are Up 3% Year Over Year, Biggest Increase Since November

Redfin Reports Home Prices Are Up 3% Year Over Year, Biggest Increase Since November

A lack of homes for sale is pushing prices up. Inventory posted its biggest decline in 18 months as homeowners cling to relatively low mortgage rates.

SEATTLE–(BUSINESS WIRE)–
(NASDAQ: RDFN) — The typical U.S. home sold for roughly $382,000 during the four weeks ending July 23, up 2.6% from a year earlier, the biggest increase since November. That’s according to a new report from Redfin (redfin.com), the technology-powered real estate brokerage.

Still, homebuyers are getting a bit of relief as mortgage rates inch down from the eight-month high hit a few weeks ago. The typical monthly mortgage payment is $2,599 at today’s average weekly rate, down $55 from the all-time high of $2,654 in early July.

Today’s housing market is unusual because prices are increasing despite lukewarm demand. Redfin’s Homebuyer Demand Index—a measure of requests for tours and other homebuying services from Redfin agents—is down 3% from a year ago, and mortgage-purchase applications are down about 23%. But inventory has dropped more than demand, with homeowners hanging onto their comparatively low mortgage rates, which is sending prices up. New listings are down 22% from a year ago, and the total number of homes for sale is down 17%, the biggest decline in a year and a half. Pending sales are down 15%, partly because the lack of inventory is tying potential homebuyers’ hands.

This week’s news that the Fed is no longer forecasting a broad economic recession is hopeful for the housing market, despite the simultaneous interest-rate hike. The Fed indicated that a soft landing is more likely than they had previously thought, which would mean interest rates went high enough to tame inflation but not enough to cause a surge in unemployment and send the economy into a recession.

“This is hopeful news for the housing market in a few ways,” said Redfin Economic Research Lead Chen Zhao. “Avoiding a recession means Americans will hold onto their jobs, for the most part, and feel more confident about purchasing big-ticket items like a house. Steady progress on taming inflation means that while mortgage rates will probably stay elevated for at least a few months, they’re likely to start coming down before the end of the year. That should encourage some sellers and buyers to jump into the market.”

Leading indicators of homebuying activity:

  • The daily average 30-year fixed mortgage rate was 6.95% on July 26, up slightly from a week earlier. For the week ending July 20, the average 30-year fixed mortgage rate was 6.78%, down from a half-year high a week earlier.

  • Mortgage-purchase applications during the week ending July 21 declined 3% from a week earlier, seasonally adjusted. Purchase applications were down 23% from a year earlier.

  • The seasonally adjusted Redfin Homebuyer Demand Index was down 3% from a year earlier, the first decline after eight straight weeks of increases.

  • Google searches for “homes for sale” were up essentially flat from a month earlier during the week ending July 22, and down about 6% from a year earlier.

  • Touring activity as of July 23 was up 11% from the start of the year, compared with a 4% decrease at the same time last year, according to home tour technology company ShowingTime.

Key housing market takeaways for 400+ U.S. metro areas:

Unless otherwise noted, this data covers the four-week period ending July 23. Redfin’s weekly housing market data goes back through 2015. For bullets that include metro-level breakdowns, Redfin analyzed the 50 most populous U.S. metros. Select metros may be excluded from time to time to ensure data accuracy.

  • The median home sale price was $381,750, up 2.6% from a year earlier. That’s the biggest increase since November.

  • Sale prices increased most in Miami (11.9% YoY), Milwaukee (9.3%), Cincinnati (8.9%), Anaheim, CA (8.3%) and West Palm Beach, FL (7.4%).

  • Home-sale prices declined in 20 metros, with the biggest drops in Austin, TX (-8.8% YoY), Detroit (-6.4%), Phoenix (-4.7%), Las Vegas (-3.9%) and Sacramento (-3.8%).

  • The median asking price of newly listed homes was $390,088, up 2.4% from a year earlier. That’s the biggest increase since January.

  • The monthly mortgage payment on the median-asking-price home was $2,599 at a 6.78% mortgage rate, the average for the week ending July 20. That’s down about 2% from the record high hit two weeks earlier, but up 16% from a year earlier.

  • Pending home sales were down 14.8% year over year, continuing a year-plus streak of double-digit declines.

  • Pending home sales fell in all but two of the metros Redfin analyzed. They declined most in New Brunswick, NJ (-32.7% YoY), Newark, NJ (-32.1%), Providence, RI (-27.8%), Warren, MI (-27%) and Boston (-25.4%). They increased 2.7% in Las Vegas and 1.4% in Austin.

  • New listings of homes for sale fell 21.6% year over year. That’s a substantial decline, but the smallest in nearly three months.

  • New listings declined in all metros Redfin analyzed. They fell most in Las Vegas (-45.2% YoY), Phoenix (-38.9%), Newark, NJ (-34.3%), Providence, RI (-32.9%) and New Brunswick, NJ (-31.7%).

  • Active listings (the number of homes listed for sale at any point during the period) dropped 16.9% from a year earlier, the biggest drop since February 2022. Active listings were down slightly from a month earlier; typically, they post month-over-month increases at this time of year.

  • Months of supply was 2.8 months, the highest level since March. Four to five months of supply is considered balanced, with a lower number indicating seller’s market conditions.

  • 43.9% of homes that went under contract had an accepted offer within the first two weeks on the market, on par with the share a year earlier.

  • Homes that sold were on the market for a median of 27 days, up from 22 days a year earlier.

  • 36.3% of homes sold above their final list price, down from 45% a year earlier.

  • On average, 5.7% of homes for sale each week had a price drop, slightly below 6% a year earlier.

  • The average sale-to-list price ratio was 100%. That’s down from 101% a year earlier.

To view the full report, including charts, please visit: https://www.redfin.com/news/housing-market-update-biggest-home-price-increase-since-november

About Redfin

Redfin (www.redfin.com) is a technology-powered real estate company. We help people find a place to live with brokerage, rentals, lending, title insurance, and renovations services. We sell homes for more money and charge half the fee. We also run the country’s #1 real estate brokerage site. Our home-buying customers see homes first with on-demand tours, and our lending and title services help them close quickly. Customers selling a home in certain markets can have our renovations crew fix up their home to sell for top dollar. Our rentals business empowers millions nationwide to find apartments and houses for rent. Customers who buy and sell with Redfin pay a 1% listing fee, subject to minimums, less than half of what brokerages commonly charge. Since launching in 2006, we’ve saved customers more than $1.5 billion in commissions. We serve more than 100 markets across the U.S. and Canada and employ over 5,000 people.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

Redfin Journalist Services:

Kenneth Applewhaite, 206-588-6863

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Construction & Property Residential Building & Real Estate

MEDIA:

Logo
Logo
Posted on

Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients

Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients

Fifty patient advocacy organizations from around the world awarded a $5,000 grant to address unique challenges faced in rare disease communities

DUBLIN–(BUSINESS WIRE)–
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 #RAREis™ Global Advocate Grant. These rare disease patient advocacy organizations will receive a one-time grant of $5,000 to establish new programs, develop educational resources and expand their current offerings to support their disease communities.

“At Horizon, our inclusive approach to supporting patient advocacy groups helps these organizations address the most critical needs affecting their rare disease community,” said Matt Flesch, vice president, communications and patient advocacy, Horizon. “We learn from every rare disease organization we interact with and are inspired by the diversity of initiatives advancing education, treatments and more. We find great meaning and purpose in this opportunity to help many different organizations – none of whom operate within any of the disease areas where Horizon makes medicines available – advance their mission.”

The 2023 #RAREis Global Advocate Grant program was announced in February during Rare Disease Day. Horizon received nearly 190 applications, from 33 countries, representing more than 180 different rare diseases. The 50 organizations awarded the grant in 2023 represent 12 countries and focus on supporting 40 different rare diseases. Eight of the advocacy groups are recipients again this year, enabling continued programming from 2022.

2023 Awardees:

  • Aliança Distrofia Brasil

  • Alliance for Pulmonary Hypertension

  • Associazione Italiana Sindrome di Beckwith-Wiedemann ODV

  • Associazione Sindrome di Noonan e RASopatie ODV

  • Avery’s Hope

  • Beck-Fahrner Syndrome Foundation

  • Brazilian Association of Prader-Willi Syndrome

  • Bulgarian Society of the Patients with PH

  • CACNA1A Foundation, Inc.

  • Chordoma Foundation

  • ConRett ETS

  • DEBRA Ireland

  • EBF3 HADDS Foundation

  • European Huntington Association

  • Erdheim-Chester Disease Global Alliance

  • Foundation for Sarcoidosis Research

  • GACI Global

  • Glanzmann’s Research Foundation, Inc.

  • Healthcare Education Institute

  • Hypertrophic Olivary Degeneration Association

  • Indo US Organization for Rare Diseases

  • Instituto Atlas Biosocial

  • International Gaucher Alliance

  • International Patient Organisation for Primary Immunodeficiencies

  • Jansen de-Vries Syndrome Foundation

  • Koolen de-Vries Syndrome Foundation

  • Lennox-Gastaut Syndrome Foundation

  • MEPAN Foundation

  • Nederlandse Leverpatienten Vereniging

  • NF Patients United – Global Network of Neurofibromatosis Patient Organizations

  • NGO Rare Diseases of Ukraine

  • Northern Ireland Rare Disease Partnership

  • Osteogenesis Imperfecta Foundation

  • Pediatric Epilepsy Surgery Alliance

  • Progressive Familial intrahepatic Cholestasis Network

  • Philippine Society for Orphan Disorders, Inc.

  • Paroxysmal Nocturnal Hemoglobinuria Ukraine

  • Project FAVA

  • Rare Disease Ghana Initiative

  • Recurrent Respiratory Papillomatosis Foundation

  • SCN2A Italia Famiglie In Rete APS

  • SHINE Syndrome Foundation

  • Soft Bones, Inc.

  • Spinal Leak CSF Foundation

  • TANGO2 Research Foundation

  • TBX4Life

  • The E.WE Foundation

  • The Rory Belle Foundation

  • Uniti per la P.I.P.O. ETS

  • Usher Syndrome Ireland

Applications are evaluated based on the organization’s work to support the rare disease community and how the grant would further their ability to deliver on their missions and goals. For more information about #RAREis, the Global Advocate Grant and to view the full list of the recipient organizations, click here.

The #RAREis Global Advocate Grant is part of Horizon’s #RAREis program, which is committed to improving the experience of living with a rare disease, by providing support to many organizations that offer crucial programs and services for people living with rare diseases. The Global Advocate Grant program launched in 2022 to provide critical financial assistance and build equity for the rare disease community by fostering growth for advocacy organizations around the world.

About #RAREis

In February of 2017, Horizon launched the #RAREis program aimed at elevating the voices, faces and experiences of people living with rare diseases, as well as highlight programs and resources for the rare disease community. The program is anchored by an Instagram page and website that showcases photos and stories of people touched by rare disease and captures elements of their patient, caregiver or advocate experience. To learn more, visit the #RAREisInstagram and Facebook page and visit the website at www.RAREisCommunity.com.

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

U.S. Media:

Michelle Rivas

Senior Manager, Communications

[email protected]

Ireland Media:

Eimear Rigby

Associate Director, Communications

[email protected]

KEYWORDS: Europe Ireland United States North America New York

INDUSTRY KEYWORDS: Philanthropy Health Other Philanthropy Other Health General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Duos Technologies Delivers Near Real-Time Defect Identification Automation

Machine Vision Railcar Inspection System for Increased Performance, Safety, and Reliability

JACKSONVILLE, Fla., July 27, 2023 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), through its operating subsidiary Duos Technologies, Inc., a provider of machine vision and artificial intelligence that analyzes fast moving vehicles, issued a statement today highlighting significant upgrades to its centraco® and truevue360™ systems. Both systems are responsible for processing and communicating near real-time analysis of car conditions to customers and subscribers.

Railcars contain hundreds of parts and critical components that must be regularly inspected to ensure safe and reliable operations. Duos works with its customers to understand their priorities and develops detection models based on key inspection points where those parts are most likely to malfunction. These inspection points are the focal areas for the Company’s wayside detection technology. Once the points have been scanned, the imaging results are communicated to mechanical inspectors via near real-time alerts and notifications so that any required or precautionary repairs can quickly take place.

The recently released performance enhancements further reduce the inspection cycle time by immediately drawing attention to the most critical areas. In addition, the upgraded system has added capabilities that allow railroad customers to immediately alert the on-board personnel of any issue that is deemed critical.

“Our developers and partners have taken another meaningful step in improving the capabilities of our systems and have brought us closer to eliminating the delay between defect scans and notifications,” said Duos Chief Executive Officer Chuck Ferry. “While our systems have always performed to a very high standard, the new implementation helps support both new and existing customers as they seek to drive improved safety and greater consistency with near real-time feedback. Our systems’ increased timing and on-board notifications will be major proof points as we continue to validate our subscription offering to the North American rail industry.”

With a major focus on AI, Duos has been working with several infrastructure partners to drive higher performance. Beyond simple imaging, the Company’s Railcar Inspection Portal (“rip®” or “RIP”) is a comprehensive, AI-driven inspection solution that utilizes AI infrastructure platforms such as Dell Technologies and NVIDIA. Duos, an NVIDIA Metropolis partner, uses NVIDIA L4 GPUs to power its AI-enabled railcar inspection systems.

Duos recently issued a press release citing how their customers are increasingly implementing targeted AI to enhance their inspections.

To stay up to date on the Company’s most recent developments or to learn more about the Duos story and its revolutionary technology platforms, be sure to follow here or sign up for email alerts here. For more information please contact [email protected] or visit the Company’s website and social media channels: Website, LinkedIn, Twitter.

About Duos Technologies Group, Inc.

Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiary, Duos Technologies, Inc., designs, develops, deploys and operates intelligent vision based technology solutions supporting rail, logistics, intermodal and government customers that streamline operations, improve safety and reduce costs. The Company provides cutting edge solutions that automate the mechanical and security inspection of fast-moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. For more information, visit www.duostech.com.


Forward- Looking Statements


This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects — both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as “believe,” “expect,” “anticipate,” “should,” “planned,” “will,” “may,” “intend,” “estimated,” and “potential,” among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. All forward-looking statements attributable to Duos Technologies Group, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c853cffb-afaf-4c81-80bb-92b649bd01e2



Contacts
Corporate
Fei Kwong, Director, Corporate Communications
Duos Technologies Group, Inc. (Nasdaq: DUOT)
904-652-1625
[email protected]

Investor Relations
Matt Glover or Tom Colton
Gateway Investor Relations
949-574-3860
[email protected]

Posted on

Monster Beverage to Report Financial Results for 2023 Second Quarter on August 3, 2023

Company to Conduct Conference Call at 2 p.m. Pacific Time

CORONA, Calif., July 27, 2023 (GLOBE NEWSWIRE) — Monster Beverage Corporation (NASDAQ: MNST) announced today that results for its second quarter ended June 30, 2023 will be reported on Thursday, August 3, 2023, after the close of the market. The company also said that Co-Chief Executive Officers, Rodney Sacks and Hilton Schlosberg, will host an investor conference call that same day at 2 p.m. Pacific Time to review the company’s financial results and operations.

The call will be open to all interested investors through a live audio webcast via the Internet at www.monsterbevcorp.com. For those who are not able to listen to the live broadcast, the call will be archived for approximately one year on the website.

Monster Beverage Corporation

Based in Corona, California, Monster Beverage Corporation is a holding company and conducts no operating business except through its consolidated subsidiaries. The Company’s subsidiaries develop and market energy drinks, including Monster Energy® drinks, Monster Energy Ultra® energy drinks, Juice Monster® Energy + Juice energy drinks, Java Monster® non-carbonated coffee + energy drinks, Rehab® Monster® non-carbonated energy drinks, Monster Hydro® non-carbonated refreshment + energy drinks, Monster Energy® Nitro energy drinks, Reign Total Body Fuel® high performance energy drinks, Reign Inferno® thermogenic fuel high performance energy drinks, Reign Storm® clean energy drinks, NOS® energy drinks, Full Throttle® energy drinks, BPM® energy drinks, BU® energy drinks, Burn® energy drinks, Gladiator® energy drinks, Live+® energy drinks, Mother® energy drinks, Nalu® energy drinks, Play® and Power Play® (stylized) energy drinks, Relentless® energy drinks, Samurai® energy drinks, Ultra Energy® drinks, Predator® energy drinks and Fury® energy drinks. The Company’s subsidiaries also develop and market still and sparkling waters under the Monster Tour Water® brand name. The Company’s subsidiaries also develop and market craft beers, hard seltzers and flavored malt beverages under a number of brands, including Jai Alai® IPA, Dale’s Pale Ale®, Dallas Blonde®, Wild Basin® hard seltzers and The Beast Unleashed™. For more information visit www.monsterbevcorp.com.

CONTACTS:   Rodney C. Sacks / Hilton H. Schlosberg
    Co-Chief Executive Officers
    (951) 739-6200
     
    Roger S. Pondel / Judy Lin
    PondelWilkinson Inc.
    (310) 279-5980



Posted on

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

  • The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of RVT-3101 in patients with moderate to severely active Crohn’s disease (CD)
  • Roivant recently announced highly favorable results from the TUSCANY-2 Phase 2b study in ulcerative colitis (UC), demonstrating improved efficacy from the induction to maintenance period of treatment with RVT-3101
  • Telavant plans to initiate a Phase 3 inflammatory bowel disease (IBD) program in patients with moderate to severely active UC

NEW YORK and BASEL, Switzerland, July 27, 2023 (GLOBE NEWSWIRE) — Telavant, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics to help patients living with inflammatory and fibrotic diseases, announced today the initiation of the TAHOE study, a Phase 2 clinical trial of RVT-3101 for the treatment of moderate to severely active CD, with first patient dosed.

The TAHOE study (NCT05910528) is a global, randomized, double-blind study evaluating two doses of RVT-3101 given once-monthly in patients with moderate to severely active Crohn’s disease. The primary and key secondary endpoints are the proportion of participants achieving clinical remission by Crohn’s Disease Activity Index (CDAI) and the proportion of participants achieving endoscopic response at week 14.

“We are excited to broaden the potential of RVT-3101 with the initiation of the TAHOE Phase 2 study as we believe its novel mechanism of action, addressing both inflammation and fibrosis, can make a significant impact on patients suffering with Crohn’s disease,” said Bittoo Kanwar, Chief Medical Officer of Telavant. “We look forward to evaluating RVT-3101’s potential to address the high unmet need that exists in this patient population.”

“Despite the availability of multiple treatment options, many Crohn’s disease patients do not achieve adequate disease control,” said Professor Geert D’Haens, gastroenterologist and investigator at Amsterdam UMC. “TL1A provides a compelling therapeutic target to treat inflammatory bowel diseases and the IBD community is excited about the potential for RVT-3101 as a new treatment approach for UC and CD patients.”

“This is an exciting milestone for Telavant as we continue to expand the opportunities for RVT-3101,” said Frank Torti, Chief Executive Offer of Telavant and Vant Chair at Roivant. “Building on the successful Phase 2 trial in UC, expansion into CD is the next step in applying this unique mechanism to bring solutions and value to the healthcare community.”

Roivant recently reported chronic period data for RVT-3101 from the TUSCANY-2 Phase 2b study in UC, demonstrating improved efficacy from the induction to chronic period. This was the first-ever long-duration data reported for an anti-TL1A antibody. At the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved clinical remission (36% at week 56 vs. 29% at week 14) and endoscopic improvement (50% vs. 36%). At the expected Phase 3 once-monthly subcutaneous dose in the biomarker positive population, RVT-3101 treatment resulted in improved clinical remission1 (43% at week 56 vs. 33% at week 14) and endoscopic improvement2 (64% vs. 47%). Across all doses and patient groups, RVT-3101 was well tolerated and showed a favorable safety profile.

About Inflammatory Bowel Disease and Crohn’s Disease

Inflammatory bowel diseases are chronic inflammatory diseases of the gastrointestinal (GI) tract. It is estimated that up to 2 million US adults suffer from inflammatory bowel diseases, which include ulcerative colitis and Crohn’s disease. Crohn’s disease is characterized by inflammation in one or more portions of the GI tract, including the mouth, small intestine, or colon, with segments of normal tissue in between. Inflammation in CD can affect all layers of tissue and may lead to fibrosis and obstructions. Therapeutic response to medications varies across patients, and poor prognostic indicators and lack of biomarkers lead to a “trial and error” treatment paradigm. Even the best advanced therapies typically result in 10-15% remission of disease, leaving frequent flare-ups, continued worsening of disease, or serious complications like intestinal fibrosis that may require surgery. Many patients that achieve remission on a therapy will stop responding to it over time, and no approved medication directly addresses the fibrotic component of IBD.

About Telavant

Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases. Telavant is developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn’s disease, including for patients with a prospectively defined biomarker who may benefit from a precision approach utilizing RVT-3101.

For more information, please visit www.telavanttx.com.

About Roivant

Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Today, Roivant’s pipeline is concentrated in inflammation and immunology and includes VTAMA®, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (“FcRn”) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to several other therapies in various stages of clinical development. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit www.roivant.com.

Roivant Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our products and product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our products and product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Investors

Roivant Investor Relations
[email protected]

Media

Stephanie Lee
Roivant Sciences
[email protected]

1 Clinical Remission for RVT-3101 is defined as an endoscopic subscore ≤1, ≥1-point decrease from baseline to achieve a stool frequency subscore of ≤1, and rectal bleeding subscore of 0

2 Endoscopic Improvement for RVT-3101 is defined as an endoscopic subscore ≤1 



Posted on

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

TEL AVIV, Israel–(BUSINESS WIRE)–
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva’s US headquarters in Parsippany, NJ.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230727524382/en/

(Photo: Business Wire)

(Photo: Business Wire)

Dr. Grant joins Teva with over 25 years of experience in the global pharmaceutical and biotech industry, with an exceptional track record across a variety of fields including Business Development, R&D and Regulatory Affairs. Most recently, Dr. Grant served as the Chief Business Executive at BeiGene, overseeing business development, clinical and business insights and valuation, investments and collaborations, and alliance management. Before his tenure at BeiGene, Dr. Grant served as CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Earlier in his career, Dr. Grant spent 12 years at Celgene, serving in various leadership roles including Corporate Vice President of Business Development, and Vice President, Regulatory Affairs.

Richard Francis, Teva’s President and CEO said: “We are pleased to welcome a leader of Angus caliber to our executive team at Teva. With a distinguished career spanning over more than two and a half decades in the global pharmaceutical and biotech industry, his breadth of experience and demonstrated expertise in business development, innovative R&D, and scientific affairs will be a significant asset to our organization.

Mr. Francis continued: “These are exciting times at Teva, as we embark on our Pivot to Growth strategy, a crucial element of which involves amplifying our innovation through our already promising pipeline as well as fortifying our business development endeavors. I have full confidence in Angus leadership and firmly believe that he is exceptionally positioned to lead the business development efforts during this era of transformation. His contributions will be instrumental in driving external innovation, fostering collaborations across academia, biotech, and pharmaceutical sectors, and enhancing Teva’s momentum in bringing innovative therapies to patients worldwide.”

Dr. Grant stated, “I am thrilled to be joining Teva’s executive leadership team and am inspired by Teva’s purpose and strategy to drive growth by stepping up and leaning more into innovation. I am looking forward to work with the extended Teva team and leading the excellent business development team, to drive innovation and to partner with the best minds in academia and the industry to bring meaningful impact and value for patients worldwide and for Teva.”

Angus Grant bio

Angus has held executive leadership positions at BeiGene, a global, commercial-stage biotechnology company, where he led Strategy and Partnering. Angus also served as CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease and in senior leadership positions at Celgene. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham. After completing his PhD in Anatomy/ Immunology, Angus joined a clinical laboratory within the NIH prior to joining the FDA where he focused on cell and gene therapy IND processing.

In 2006, Angus joined Celgene and held various leadership over his 12 years, including Corporate VP Business Development. Angus led deals ranging from R&D and commercialization collaborations to early equity investments, supply collaborations, M&A such as $9B Juno acquisition in 2018, and licensing both globally and regionally.

Angus departed Celgene to serve as CEO of Dementia Discovery Fund (DDF), inspired by their mission to invest in and build the early-stage biotech companies most likely to develop transformative treatments for neurodegenerative diseases, to the benefit of the millions of people suffering from this health crisis of the 21st century that has longed lacked effective treatments.

Dr. Grant received his undergraduate degree from the University of Richmond and a Ph.D. in anatomy and immunology from the Medical College of Virginia, and he completed his postdoctoral training at the National Cancer Institute. Dr. Grant currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. He is a published scientist, co-authoring more than 15 articles in peer-reviewed scientific journals.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative medicines research and operations supporting our growing portfolio of innovative medicines and biopharmaceutical products.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to our business and operations in general, including our ability to attract, hire and retain highly skilled key personnel, our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to execute on our Pivot to Growth strategy; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2023 and in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

IR Contacts

United States

Ran Meir (267) 468-4475

Israel

Yael Ashman 972 (3) 914-8262

PR Contacts

United States

Kelley Dougherty (973) 658-0237

Israel

Eden Klein 972 (3) 906-2645

KEYWORDS: New Jersey United States North America Israel Middle East

INDUSTRY KEYWORDS: Biotechnology Health Science Pharmaceutical Research

MEDIA:

Logo
Logo
Photo
Photo
(Photo: Business Wire)
Posted on

Tennessee Getting Latest Upgrade to its Xfinity 10G Network

Tennessee Getting Latest Upgrade to its Xfinity 10G Network

Multi-gig Speeds will be Among the Fastest in the Region

NASHVILLE, Tenn.–(BUSINESS WIRE)–
Comcast is accelerating the nation’s largest and fastest multi-gig deployment and announced today that its latest Xfinity 10G Network updates are rolling out to homes and businesses across Middle, West and East Tennessee. These network enhancements will benefit customers at all speed-tiers and price points. With these improvements, Comcast is also rolling out new download speeds up to 2 gigabits-per-second (Gbps) and up to 5x-to-10x faster upload speeds.

These Tennessee markets are the latest communities in Comcast’s southeastern region to roll out these Xfinity 10G Network enhancements, setting the stage for the introduction of new symmetrical multi-gigabit internet options that can be delivered across Comcast’s existing networks with less cost.

“Connecting Tennesseans to fast, secure and reliable internet service has never been more critical,” said Jason Gumbs, Regional SVP at Comcast. “Through our network innovation and investments, we continue to connect more residents and businesses while partnering with the state to expand our network to rural and underserved areas.”

Comcast has invested nearly $629 million in technology and infrastructure improvements in its Tennessee network over the last three years.

Powered by the Xfinity 10G Network

Comcast’s network and Internet experience are powering homes and businesses today and into the future:

  • Ultimate Capacity: Xfinity customers connect nearly 1 billion devices across the company’s network annually. The Xfinity 10G Network with the next-generation Xfinity gateways deliver the most advanced WiFi technology carrying three times more bandwidth to power streaming, gaming, videoconferencing, and more, simultaneously.
  • Fastest Internet: More than a third of Xfinity Internet customers subscribe to gigabit speed products, and symmetrical gig speeds are planned to come to the first homes later this year.
  • Unprecedented Coverage: The latest Xfinity Gateway provides a more reliable connection throughout the home. Customers can get wall-to-wall WiFi coverage with a powerful Xfinity WiFi Boost Pod that extends coverage to hard-to-reach areas, with plans for an offering of increased support for in-home WiFi through a “boost guarantee” later this year.
  • Most Reliable Connection: Comcast is scaling the nation’s largest and most reliable network – the Xfinity 10G Network – that passes 60 million homes and businesses and counting. The company plans to launch a new device that is “storm ready” with cellular and battery backup to help keep customers connected even when the power goes out.
  • Ultra-Low Latency: The Xfinity 10G Network and the latest Xfinity Gateway are a powerful combination that deliver ultra-low latency for those moments when response times matter most like video games, a fast-growing category with Xfinity households averaging more than one gaming console per home.

Recently, Comcast accelerated the transformation of its network to a cloud-based architecture that is fully prepared for robust 10G technologies and DOCSIS 4.0. This network architecture will enable Comcast to deliver symmetrical, multi-gigabit speeds to both residential and business customers, services that technically limited fixed wireless providers will not be able to deliver. Comcast’s ongoing network evolution also furthers its commitment to provide a cleaner, greener Internet by doubling network energy efficiency by 2030. Comcast estimates this will avoid the equivalent amount of electricity needed to power a half a million homes for a year.

More information about the Xfinity 10G Network can be found here.

About Comcast Corporation

Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information.

Media

Sara Jo Walker

Senior Director of Public Relations

Comcast

615.417.4899

KEYWORDS: United States North America Tennessee

INDUSTRY KEYWORDS: Data Management Consumer Electronics Technology Online VoIP Mobile/Wireless Entertainment Semiconductor Security Satellite Photography Nanotechnology Other Technology Audio/Video Telecommunications Software Networks Internet Hardware Electronic Design Automation

MEDIA:

Logo
Logo
Posted on

NICE Introduces Generative AI-Powered “Enlighten Actions Industry Benchmarks,” Allowing Brands a Unique Way to Create Stronger Brand Loyalty

NICE Introduces Generative AI-Powered “Enlighten Actions Industry Benchmarks,” Allowing Brands a Unique Way to Create Stronger Brand Loyalty

With this groundbreaking capability, organizations can now create differentiating service by comparing their key metrics and service insights to industry standards with a click of a button

HOBOKEN, N.J.–(BUSINESS WIRE)–NICE (Nasdaq: NICE) today announcedIndustry Benchmarks, augmenting Enlighten Action’s generative AI-powered capabilities to allow brands to holistically compare their operations to industry standards. This enhances Enlighten Actions, using large language models to create stronger brand loyalty for consumers and allow business users to interact with data in a conversational way.

With Enlighten Actions Industry Benchmarks, companies have access to anonymized benchmarked interaction level data, from more than 75 industries, for all interaction intents to holistically compare their operations to their specific vertical. This benchmark information relates to call reasons, handle time, CSAT, agent behaviors, complaints, sales effectiveness, scheduling levels, training, automation, and more. For the first time, companies will be able to see how their service level compares to other companies in their industry and understand the opportunities to optimize service and training and reduce costs through self-service.

Barry Cooper, President, CX Division, NICE, said, “The ability to ensure the highest level of service is key to creating and increasing brand loyalty and to creating differentiating CX. The addition of Industry Benchmarks to Enlighten Actions is a significant leap forward and is quickly becoming a must-have for organizations in their constant effort to enhance and optimize their customer experience.”

“Brands across all industries are looking for practical ways to apply conversational AI to improve employee performance and bottom-line results,” explains Dan Miller, lead analyst at Opus Research. “NICE’s Industry Benchmarks opens up a broad opportunity for executives to harness the power of generative AI and large language models to ensure their customer and employee experiences exceed those of their competition.”

About NICE

With NICE (Nasdaq: NICE), it’s never been easier for organizations of all sizes around the globe to create extraordinary customer experiences while meeting key business metrics. Featuring the world’s #1 cloud native customer experience platform, CXone, NICE is a worldwide leader in AI-powered self-service and agent-assisted CX software for the contact center – and beyond. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, partner with NICE to transform – and elevate – every customer interaction. www.nice.com

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Corporate Media

Christopher Irwin-Dudek, +1 201 561 4442, [email protected], ET

Investors

Marty Cohen, +1 551 256 5354, [email protected], ET

Omri Arens, +972 3 763 0127, [email protected], CET

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Software Other Communications Artificial Intelligence Data Management Communications Technology Apps/Applications Other Technology

MEDIA:

Logo
Logo
Posted on

ICE’s Global Commodity and Energy Markets Reach Record Open Interest

ICE’s Global Commodity and Energy Markets Reach Record Open Interest

LONDON & NEW YORK & AMSTERDAM–(BUSINESS WIRE)–
Intercontinental Exchange, Inc. (NYSE:ICE), a leading global provider of data, technology, and market infrastructure, today announced record open interest (OI) across its global commodity and energy futures and options markets.

On July 25, 2023, ICE hit record OI of 55.4 million contracts across commodities futures and options, up 14% year-over-year (y/y), with record OI of 50.9 million in energy futures and options, also up 14% y/y. OI across ICE’s commodity options portfolio continues to perform strongly, up 25% y/y at 20.6 million, with ADV up 27%, while energy options OI is up 26% y/y at 18.5 million, with ADV up 28% y/y.

ICE offers the most liquid markets to trade energy. Across ICE’s global oil markets, OI is up 17% y/y at 12.3 million, with OI in Brent futures and options up 14% y/y at 5 million. Brent is used to price over three quarters of the world’s internationally traded crude oil and is the most liquid crude oil futures and options market in the world.

Other oil benchmarks performing strongly include Gasoil where OI is up 49% y/y at 788,500; ICE Dubai (Platts) where OI is up 56% y/y at a record 899,931 contracts; Murban where OI is up 39% y/y at 56,200; and Midland WTI (HOU) which hit record OI of 33,520 this month. HOU is delivering 5 million barrels each month of Midland WTI quality crude, which is deliverable into the Brent basket.

“Customers are drawn to the breadth of ICE’s global benchmarks across oil, natural gas, environmentals and soft commodities, utilizing the liquidity and transparency of our markets to hedge their risk, while using the real time price signals to make decisions, including on where to send commodities around the world, where to invest, and what products to produce,” said Trabue Bland, SVP, Futures Markets at ICE.

Across ICE’s global natural gas portfolio, OI is up 16% y/y at 33.3 million contracts, with OI across North American natural gas futures and options, which includes Henry Hub and U.S. Basis Markets contracts, up 14% at 29.7 million. OI in ICE TTF natural gas is up 39% y/y at 2.9 million, the highest levels since December 2021, with record market participation in TTF futures and options through the first half of 2023.

In ICE’s global environmental portfolio, which alongside ICE’s energy markets provide price signals and liquidity to help companies transition to alternative forms of energy and make decisions on how to invest in renewable energy projects, OI is at 1.87 million contracts.

About Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks to connect people to opportunity. We provide financial technology and data services across major asset classes that offer our customers access to mission-critical workflow tools that increase transparency and operational efficiencies. We operate exchanges, including the New York Stock Exchange, and clearing houses that help people invest, raise capital and manage risk across multiple asset classes. Our comprehensive fixed income data services and execution capabilities provide information, analytics and platforms that help our customers capitalize on opportunities and operate more efficiently. At ICE Mortgage Technology, we are transforming and digitizing the U.S. residential mortgage process, from consumer engagement through loan registration. Together, we transform, streamline and automate industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading “Key Information Documents (KIDS).”

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 — Statements in this press release regarding ICE’s business that are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE’s Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 2, 2023.

Category: EXCHANGES

ICE- CORP

Source: Intercontinental Exchange

ICE Media Contact:

Rebecca Mitchell

[email protected]

+44 7951 057 351

ICE Investor Contact:

Katia Gonzalez

[email protected]

(678) 981-3882

KEYWORDS: New York Netherlands North America United States United Kingdom Europe

INDUSTRY KEYWORDS: Finance Oil/Gas Energy Professional Services Fintech

MEDIA:

Logo
Logo